Class / Patent application number | Description | Number of patent applications / Date published |
530330000 | 4 to 5 amino acid residues in defined sequence | 67 |
20090105449 | Novel Ph Dependent Adhesive Peptides - A novel peptide adhesive motif is described that requires no receptor or cross-links to achieve maximal adhesive strength. Several peptides with different degrees of adhesive strength have been designed and synthesized using solid phase chemistries. All peptides contain a common hydrophobic core sequence flanked by positively or negatively charged amino acids sequences. | 04-23-2009 |
20090176967 | Conjugation of FVII - New FVII polypeptides and FVIIa derivatives, uses of such peptides, and methods of producing these polypeptides and derivatives, are provided. | 07-09-2009 |
20090209728 | Peptides That Increase Collagen or Hyaluronic Acid Production - The present invention relates to a novel peptide having a specified amino acid sequence or its derivative, or a salt thereof. Further, the present invention relates to a composition containing the novel peptide or the like, a method of utilizing the novel peptide or the like, use of the novel peptide or the like, a polynucleotide encoding the novel peptide, or the like. The novel peptide of the present invention or its derivative, or a salt thereof can be utilized for enhancing production of at least one member selected from the group consisting of collagen and hyaluronic acid in a cell. | 08-20-2009 |
20100063252 | PROCESSES AND INTERMEDIATES - The invention relates to compounds and processes useful for the preparation of protease inhibitors, particularly serine protease inhibitors. The protease inhibitors are useful for treatment of HCV infections. | 03-11-2010 |
20100168384 | ANTI-VIRAL COMPOUNDS - Compounds capable of inhibiting replication of the hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection. | 07-01-2010 |
20100240867 | FLUORENE COMPOUND - Particular compounds having a fluorene skeleton are superior in broad utility and stability, as a protecting reagent for liquid phase synthesis of amino acids and/or peptides. | 09-23-2010 |
20100261878 | SEQUENCES FOR FK228 BIOSYNTHESIS AND METHODS OF SYNTHESIZING FK228 AND FK228 ANALOGS - Polynucleotides encoding the polypeptides involved in biosynthesis of FK 228 and those involved in synthesis of a novel FK228 analog, thailandepsin are disclosed herein. Also provided are methods of making FK228, thailandepsin and analogs of these molecules and methods of using these FK228 analogs. | 10-14-2010 |
20100261879 | PEPTIDE DERIVATIVES AND COSMETIC COMPOSITION COMPRISING THE SAME - The present invention relates to peptide derivatives, wherein glutathione-like peptides are connected to benzoic acid derivatives, and a cosmetic composition comprising the same. The peptide derivatives according to the present invention have excellent tyrosinase inhibition and anti-oxidative activities to show excellent skin whitening effect, biocompatibility without skin stimulation, and stability during long-term storage. Therefore, they can be effectively used for a cosmetic composition for skin whitening. | 10-14-2010 |
20100324265 | PROCESS FOR THE PREPARATION GLATIRAMER ACETATE (COPOLYMER-1) - This invention relates to a convenient and improved process for preparation of glatiramer acetate (copolymer-1) of pharmaceutical grade. The process involves polymerizing N-carboxyanhydrides of tyrosine, alanine, y-benzyl glutamate and &egr;-N-trifluoroacetyllysine in dioxane with diethylamine as initiator to afford protected copolymer-1. Treatment with hydrogen bromide in acetic acid at 35° C. for 3-5 h cleaves benzyl group to produce trifluoroacetyl copolymer-1. The trifluoroacetyl copolymer-1 is washed with an organic solvent to remove reactive benzyl bromide generated during debenzylation. Deprotection with aqueous piperidine, followed by dialysis offers glatiramer acetate (copolymer-1) of Molecular weight 5000-9000 daltons. | 12-23-2010 |
20110015371 | Inhibitors of interleukin-1 beta converting enzyme - The present invention relates to novel classes of compounds which are inhibitors of interleukin-1β converting enzyme. The ICE inhibitors of this invention are characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting ICE activity and consequently, may be advantageously used as agents against interleukin-1 mediated diseases, including inflammatory diseases, autoimmune diseases and neurodegenerative diseases. This invention also relates to methods for inhibiting ICE activity and methods for treating interleukin-1 mediated diseases using the compounds and compositions of this invention. | 01-20-2011 |
20110040072 | MONO AND DI-SUBSTITUTED OXYCODONE COMPOUNDS AND COMPOSITIONS - The invention relates to pharmaceutical compounds and compositions comprised of a chemical moiety attached to oxycodone in a manner that substantially decreases the potential for overdose. When delivered at the proper dosage the pharmaceutical composition provides therapeutic activity similar to that of oxycodone and may also provide sustained release characteristics and/or reduced side-effects. Further the compounds and compositions of the invention are useful in preventing addiction and susceptibility to addiction of oxycodone. | 02-17-2011 |
20110046347 | DENDRITIC OLIGOPEPTIDE-GRAFTEDED CYCLOTRIPHOSPHAZENE, A PROCESS FOR THE PREPARATION THEREOF AND A DRUG DELIVERY SYSTEM CONTAINING THE SAME - A cyclotriphosphazene represented by Formula 1 prepared by introducing a dendritic tetrapeptide and a hydrophilic polyethylene glycol into a cyclotriphosphazene ring, a method of preparing the same, and a drug carrier including the cyclotriphosphazene of Formula 1. | 02-24-2011 |
20110118440 | GAMMA AMINO ACID BUILDING BLOCKS - The invention provides compounds and methods, for example, to carry out organocatalytic Michael additions of aldehydes to cyclically constrained nitroethylene compounds catalyzed by a proline derivative to provide cyclically constrained α-substituted-γ-nitro-aldehydes. The reaction can be rendered enantioselective when a chiral pyrrolidine catalyst is used, allowing for Michael adducts in nearly optically pure form (e.g., 96 to >99% e.e.). | 05-19-2011 |
20110190475 | PROCESSES FOR REMOVAL OF DIBENZOFULVENE - A dibenzofulvene amine adduct is removed by contacting a reaction mixture containing the dibenzofulvene amine adduct, which is obtained by reacting, for deprotection, an amino acid compound protected with an Fmoc group with an amine compound containing a nitrogen atom which is bonded to at least one hydrogen atom, with carbon dioxide, and removing the carbonate of the dibenzofulvene amine adduct. Alternatively, a dibenzofulvene amine adduct is removed by mixing a reaction mixture during a deprotection reaction of the amino acid compound protected with an Fmoc group, or after the reaction with an amine compound containing a nitrogen atom which is bonded to at least one hydrogen atom to give a mixture containing the dibenzofulvene amine adduct, contacting the mixture with carbon dioxide, and removing the carbonate of the dibenzofulvene amine adduct. | 08-04-2011 |
20110257365 | Cyclin Based Inhibitors of CDK2 and CDK4 - Structural and functional analysis of peptide inhibitor binding to the cyclin D1 groove has been investigated and used to design peptides that provide the basis for structure-activity relationships, have improved binding and have potential for development as chemical biology probes, as potential diagnostics and as therapeutics in the treatment of proliferative diseases including cancer and inflammation. | 10-20-2011 |
20110288271 | AGENT DERIVED FROM TORTOISE SPLEEN STIMULATING MAMMALIAN HEMOPOIESIS - The present invention relates to a proteinaceous extract derived from tortoise spleen and to a tetrapeptide FTGN, which have stimulatory activity on hematopoietic cells. In particular, this tetrapeptide enhances hemopoietic reconstruction, and bone marrow re-population, reduced as a consequence of a high dose of radiation or chemotherapy exposure. The invention further provides pharmaceutical compositions comprising as an effective ingredient the proteinaceous extract or the FTGN tetrapeptide and ex vivo and in vivo methods of treatment employing them. | 11-24-2011 |
20120214969 | Methods and Compositions for F-18 Labeling of Proteins, Peptides and Other Molecules - The present application discloses compositions and methods of synthesis and use of F-18 labeled molecules of use in PET imaging. In particular embodiments, the labeled molecules may be peptides or proteins, although other types of molecules may be labeled and utilized. Preferably, the F-18 is attached to a targeting molecule by formation of a metal complex and binding of the F-18-metal complex to a chelating moiety. In other embodiments, the metal may first be attached to the chelating group and subsequently the F-18 bound to the metal. More preferably, the F-18 label moiety may be attached to a targetable conjugate that is used for pretargeting in combination with a bispecific or multispecific antibody. The F-18-metal labeled molecules are stable in human serum at 37° C. | 08-23-2012 |
20120309938 | HEMIASTERLIN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CANCER - The present invention provides compounds having formula (I): | 12-06-2012 |
20120322978 | CROSSLINKING REAGENTS, METHODS, AND COMPOSITIONS FOR STUDYING PROTEIN-PROTEIN INTERACTIONS - The invention provides reagents, methods, and compositions for studying protein-protein interactions. The inventive system and methods allow the analysis of protein-protein interactions in vivo and in vitro. Advantages offered by various embodiments of the inventive system and methods compared to existing photocrosslinking approaches include, for example, (i) novel reversible crosslinking reagents that allow easy isolation, purification, and enrichment of the crosslinked products; (ii) trifluoromethyl phenyldiazirine- or perfluorinated phenylazide-based photocrosslinking reagents that provide high specific labeling, no side product, and higher photocrosslinking efficiency; (iii) versatile spacer groups that allow systematic contact site mapping; (iv) novel methods for isolating, purifying, and detecting crosslinked products based on the reversible-link chemistry; and (v) the ability to study the interaction sites in vitro, in situ, or in vivo. | 12-20-2012 |
20120329985 | Optimal hydolysis conditions of soy protein to produce peptides with lipolysis-stimulating activity and their sequencing and use thereof - This present invention discloses a method for preparing a lipolysis-stimulating soy protein hydrolysate, proceeding a hydrolysis reaction, which is a predetermined concentration of soy protein mediated by Flavourzyme in a predetermined hydrolysis conditions, wherein Flavourzyme versus the soy protein is 1:100, and the optimal hydrolysis conditions including reaction pH value 7˜7.5, reaction temperature 40˜50° C. and hydrolysis time 100˜150 minutes. This invention further discloses nine recombinations of isolated peptide sequences from the soy protein hydrolysate including Val-His-Val-Val, Leu-Leu-Leu, Leu-Leu-Ile, Leu-Ile-Leu, Leu-Ile-Ile, Ile-Leu-Leu, Ile-Leu-Ile, Ile-Ile-Leu and Ile-Ile-Ile. | 12-27-2012 |
20120329986 | HETEROPEPTIDES USEFUL FOR REDUCING NONSPECIFIC ADSORPTION - Reagents, kits, uses and methods useful for example fo decreasing nonspecific adsorption of biomolecules at the surface of a solid support are disclosed. Such reagents and methods, which are based on short heteropeptides, may be used to decrease nonspecific adsorption in for example biosensing applications. | 12-27-2012 |
20130012686 | COSMETIC COMPOSITION FOR STIMULATING THE SYNTHESIS OF PROTEINS OF THE BASEMENT MEMBRANE - Cosmetic composition which can be applied topically, comprising at least one compound of the general formula (I) in which R | 01-10-2013 |
20130046077 | DOLASTATIN 15 DERIVATIVES - Compounds of the present invention include cell growth inhibitors which are peptides of Formula I, | 02-21-2013 |
20130060006 | Natural Flavour Enhancers and Methods for Making Same - The present invention pertains to the use of certain flavour enhancing compounds obtainable from an | 03-07-2013 |
20130096277 | PROCESSES AND INTERMEDIATES - A process for preparing enantioselectively a compound of formula I-1a or I-1b: | 04-18-2013 |
20130144036 | QUINOXALINE-CONTAINING COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS - The present invention discloses compounds of formula I and II or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 06-06-2013 |
20130144037 | NOVEL LIPID PEPTIDE AND HYDROGEL - There is provided a lipid peptide that is capable of forming a hydrogel with an extremely small amount thereof over a liquid property range from acidic to alkaline, and a hydrogel having high environmental suitability, biocompatibility and biodegradability. A lipid peptide represented by Formula (1): | 06-06-2013 |
20130165631 | BISAMINOETHANETHIOL-TARGETING LIGAND CONJUGATES AND COMPOSITIONS - The invention provides, in a general sense, a new labeling strategy employing | 06-27-2013 |
20130184435 | MULTI-DRUG LIGAND CONJUGATES - Described herein are compounds, pharmaceutical compositions and methods for treating pathogenic cell populations in a patient. The compounds described herein include conjugates of a plurality of cytotoxic drugs and vitamin receptor binding ligands. The plurality of drugs may be the same or different. Similarly, the vitamin receptor binding ligands may be the same or different. The conjugates also include a linker that is formed from one or more spacer linkers, heteroatom linkers, and releasable linkers. | 07-18-2013 |
20130211044 | Methods and Compositions for Improved F-18 Labeling of Proteins, Peptides and Other Molecules - The present application discloses compositions and methods of synthesis and use of | 08-15-2013 |
20130237687 | VITAMIN-TARGETED IMAGING AGENTS - The invention relates to compounds and methods for targeting radionuclide-based imaging agents to cells having receptors for a vitamin, or vitamin receptor binding derivative or analog thereof, by using such a vitamin as the targeting ligand for the imaging agent. The invention provides a compound of the formula | 09-12-2013 |
20130237688 | MULTIMODALITY AGENTS FOR TUMOR IMAGING AND THERAPY - A compound that is a conjugate of an antagonist to an integrin expressed by a tumor cell and at least one of a tumor avid tetrapyrollic photosensitizer, a fluorescent dye, and a radioisotope labeled moiety wherein the radioisotope is | 09-12-2013 |
20130267681 | CHEMICAL LIGATION BY RING OPENING OF OXO-THIOMORPHOLINES - The invention discloses processes for preparing compounds comprising an α-amino acid motif. The compounds are useful in e.g. the chemical ligation of peptides. | 10-10-2013 |
20130281663 | PREPARATION OF POLYPEPTIDES AND SALTS THEREOF - The application relates to processes for preparing polypeptides. Also provided are processes for preparing glatiramer acetate. | 10-24-2013 |
20130289240 | Cyclin Based Inhibitors of CDK2 and CDK4 - Structural and functional analysis of peptide inhibitor binding to the cyclin D and cyclin A groove has been investigated and used to design peptides that provide the basis for structure-activity relationships, have improved binding and have potential for development as chemical biology probes, as potential diagnostics and as therapeutics in the treatment of proliferative diseases including cancer and inflammation. | 10-31-2013 |
20140066594 | BINDING LIGAND LINKED DRUG DELIVERY CONJUGATES OF TUBULYSINS - Described herein are compounds, pharmaceutical compositions and methods for treating pathogenic cell populations. The compounds described herein include conjugates of tubulysins and vitamin receptor binding ligands. The conjugates also include a releasable bivalent linker. | 03-06-2014 |
20140107317 | Selective Targeting Agents for Mitochondria - The present invention provides a composition and related methods for delivering cargo to a mitochondria which includes (a) a membrane active peptidyl fragment having a high affinity with the mitochondria and (b) cargo. The cargo may be selected from a wide variety of desired cargoes which are to be delivered to the mitochondria for a specific purpose. Compositions and methods are disclosed for treating an illness that is caused or associated with cellular damage or dysfunction which is caused by excessive mitochondrial production of reaction oxygen species (ROS). Compositions which act as mitochondria-selective targeting agents using the structural signaling of the β-turn recognizable by cells as mitochondria) targeting sequences are discussed. Mitochondria and cell death by way of apoptosis is inhibited as a result of the ROS-scavenging activity, thereby increasing the survival rate of the patient. | 04-17-2014 |
20140107318 | PROCESSES AND INTERMEDIATES - The invention relates to compounds and processes useful for the preparation of protease inhibitors, particularly serine protease inhibitors. The protease inhibitors are useful for treatment of HCV infections. | 04-17-2014 |
20140148574 | SYNTHESIS OF AN INTERMEDIATE OF AN ANTIVIRAL COMPOUND - Process for the preparation of a cyclopropylamide compound which is useful as a structural unit in a process for the preparation of a viral protease inhibitor. | 05-29-2014 |
20140155577 | SELF-ASSEMBLY OF THERAPEUTIC AGENT-PEPTIDE NANOSTRUCTURES - Disclosed are conjugates of hydrophobic drugs linked to protected or unprotected amino acids or peptides. The disclosed conjugates are amphiphilic and can self assemble into nanotubes. Nanotubes comprising the conjugates are also described and can have high loading of the drug and protect it from degradation or elimination. The nanotubes are well suited to deliver hydrophobic and unstable drugs to individuals. | 06-05-2014 |
20140179902 | TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF - Complexes of heterocyclic radionuclides are prepared based upon ligands having substituted pyridyl and imidazolyl groups. The ligands are bifunctional, having amino acid residues that may act as a linker to a bioactive molecule, and a tridentate chelator that may complex the radionuclide. The bioactive molecule may be a peptide or somatostatin. | 06-26-2014 |
20140206840 | FLUORESCENT LABELING OF LIVING CELLS - Latent fluorescent tags, including compounds of Formula I, methods of making latent fluorescent tags, and methods of fluorescently labeling living cells are provided. The compounds of Formula I have the structure: | 07-24-2014 |
20140213760 | Folate Receptor Binding Conjugates of Antifolates - Conjugates of antifolates, releasable linkers, and drugs, and pharmaceutical compositions containing them are described. The conjugates are useful for treating diseases arising from pathogenic cell populations. Methods for treating such diseases are also described. | 07-31-2014 |
20140296484 | Cyclin Based Inhibitors of CDK2 and CDK4 - Structural and functional analysis of peptide inhibitor binding to the cyclin D and cyclin A groove has been investigated and used to design peptides that provide the basis for structure-activity relationships, have improved binding and have potential for development as chemical biology probes, as potential diagnostics and as therapeutics in the treatment of proliferative diseases including cancer and inflammation. | 10-02-2014 |
20140323689 | PROCESS FOR THE PREPARATION OF A VIRAL PROTEASE INHIBITOR AND INTERMEDIATES THEREOF - Process for the preparation of a viral protease inhibitor and intermediates useful in its preparation. | 10-30-2014 |
20140364585 | IMMUNOCONJUGATES, COMPOSITIONS FOR MAKING THEM, AND METHODS OF MAKING AND USE - An immunoconjugate in which a phosphate-prodrugged DNA minor groove binding agent of formula (I), where X is a nucleophilically displaceable leaving group, is conjugated to an antibody or an antigen binding fragment of an antibody, and compounds that can be used for making such immunoconjugates, and uses of such immunoconjugates. | 12-11-2014 |
20140371424 | BENZYLIC COMPOUND - The present invention provides a protecting reagent that can be removed in a high yield even under acidic conditions and can afford a resulting product at a high purity in an organic synthesis reaction such as peptide synthesis and the like. The inventive protecting reagent is particular benzylic compound having only one hydroxyl group substituted by an organic group having an aliphatic hydrocarbon group having a carbon number of not less than 14. | 12-18-2014 |
20150011730 | Cyclin Based Inhibitors of CDK2 and CDK4 - Structural and functional analysis of peptide inhibitor binding to the cyclin D and cyclin A groove has been investigated and used to design peptides that provide the basis for structure-activity relationships, have improved binding and have potential for development as chemical biology probes, as potential diagnostics and as therapeutics in the treatment of proliferative diseases including cancer and inflammation. | 01-08-2015 |
20150018520 | INHIBITORS TARGETING HUMAN GHRELIN O-ACYLTRANSFERASE - Grhelin O-acyltransferase inhibitors using a triazole linkage to incorporate aromatic and alkyl substituents to mimic the natural octanoyl group attached to ghrelin. Inhibitors include a triazole portion, an alkyl linker, and a hydrophobic aromatic group on a side chain. The hydrophobic aromatic group may include various length alkyl linkers. | 01-15-2015 |
20150025222 | Substituted Anthraquinone Dyes for Cellular Stains and Enzyme Detection - The invention discloses new substituted anthraquinone dyes that may be useful as cellular stains. In some aspect of the invention, the nuclear stains are useful for staining the nuclei of dead or fixed cells. Another aspect of the invention relates to substituted anthraquinone dyes comprising an enzyme substrate moiety that is transformable or cleavable by an enzyme such that the transformation or cleavage of the substrate moiety causes a detectable change in the functionality or spectral properties of the dye. | 01-22-2015 |
20150038677 | PROCESS FOR THE SYNTHESIS OF TELAPREVIR, OR PHARMACEUTICALLY ACCEPTABLE SALTS OR SOLVATES AS WELL AS INTERMEDIATE PRODUCTS THEREOF - The invention relates to a process for the preparation of telaprevir, or a pharmaceutically acceptable salt or solvate thereof, wherein the process requires a smaller number of process steps and/or does not require the use of toxic and instable compounds compared to the known processes. Another embodiment refers to telaprevir, or a pharmaceutically acceptable salt or solvate thereof as well as to intermediate products for preparation of the same, wherein the afore-mentioned products are obtained by the process described herein. | 02-05-2015 |
20150065683 | OPIORPHIN PEPTIDE DERIVATIVES AS POTENT INHIBITORS OF ENKEPHALIN-DEGRADING ECTOPEPTIDASES - The present invention relates to modified opiorphin peptides as new inhibitors of metallo-ectopeptidases. | 03-05-2015 |
20150080551 | LYSINE OLIGOMER DERIVATIVE AND CARTILAGE TISSUE MARKER MADE THEREOF - There is provided a lysine oligomer derivative, wherein an ε-amino group and a carboxyl group of lysines are linked via a peptide bond, and a group capable of generating or absorbing electromagnetic wave is bonded to a C-terminal carboxyl group, an N-terminal amino group and/or an α-amino group. This lysine oligomer derivative has the characteristic of specifically accumulating in the cartilage matrix and can generate or absorb an electromagnetic wave, and is, therefore, useful as a cartilage tissue marker. | 03-19-2015 |
20150105535 | CONTROL OF COPOLYMER COMPOSITIONS - Methods of making copolymers are described. | 04-16-2015 |
20150119552 | AROMATIC-CATIONIC PEPTIDES AND USES OF SAME - Disclosed herein are compositions and methods related to aromatic-cationic peptides. In particular, the compositions and methods relate to aromatic-cationic peptides in conjunction with cytochrome c. In some embodiments, the aromatic-cationic peptide comprises one or more of D-Arg-Tyr-Lys-Phe-NH2 (P-231), DArg-D-Dmt-D-Lys-D-Phe-NH2, and D-Arg-D-Tyr-D-Lys-D-Phe-N H2 (P-2310). In some embodiments, the method relates to increasing cytochrome c reduction, enhancing electron diffusion through cytochrome c, enhancing electron capacity in cytochrome c, and/or inducing novel n-n interactions around cytochrome c. | 04-30-2015 |
20150353600 | Crystal Forms - The present invention features crystalline forms of Compound I. In one embodiment, a crystalline form of Compound I has characteristic peaks in the PXRD pattern as shown in any one of FIGS. | 12-10-2015 |
20160016995 | TUNABLE CONTROL OF PROTEIN DEGRADATION IN SYNTHETIC AND ENDOGENOUS BACTERIAL SYSTEMS - The methods and compositions described herein relate, in part, to the generation of a synthetic degradation system in | 01-21-2016 |
20160024143 | DEPROTECTION METHOD - The present invention provides a method of efficiently deprotecting a protected organic compound by catalytic hydrogenation. Specifically, the present invention provides a method of deprotecting an organic compound having at least one functional group selected from the group consisting of a carboxy group, an amino group and a hydroxy group, which is protected by a protecting group represented by the formula (I): | 01-28-2016 |
20160039871 | NOVEL FORMS OF TELAPREVIR - The invention relates to an amorphous form of telaprevir, its preparation via novel crystalline Form C of telaprevir (also referred to as “crystalline Form C” or “Form C”), and telaprevir compositions comprising said amorphous form and Form C. Furthermore, the present invention relates to the use of said amorphous telaprevir, telaprevir composition and Form C of telaprevir for the preparation of medicaments such as anti-hepatitis C medicaments. Moreover, the present invention relates to pharmaceutical compositions and dosage forms comprising a pharmaceutically effective amount of said novel forms for use in treating patients suffering from hepatitis C virus. | 02-11-2016 |
20160067341 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING - Described herein are prostate specific membrane antigen (PSMA) binding conjugates that are useful for delivering therapeutic, diagnostic and imaging agents. Also described herein are pharmaceutical composition containing them and methods of using the conjugates and compositions. Also described are processes for manufacture of the conjugates and the compositions containing them. | 03-10-2016 |
20160115198 | METHODS OF MAKING CARFILZOMIB AND INTERMEDIATES THEREOF - Racemization-free methods are disclosed for the synthesis of carfilzomib. Novel intermediates and methods of making carfilzomib employing fragment condensation using the novel intermediates are disclosed. Amorphous carfilzomib and methods of making same are disclosed. | 04-28-2016 |
20160152675 | COMPOSITIONS AND METHODS RELATED TO TAUOPATHY | 06-02-2016 |
20160177402 | IMMUNOGLOBULIN EXPRESSION LEVELS AS BIOMARKER FOR PROTEASOME INHIBITOR RESPONSE | 06-23-2016 |
20160193371 | CONJUGATES FOR IMAGING | 07-07-2016 |
20160194354 | STEREOSELECTIVE SYNTHESIS OF DIOLS AND TRIOLS BY MANNICH REACTION AND THEIR USE IN THE SYNTHESIS OF CARFILZOMIB | 07-07-2016 |
20160194356 | AROMATIC-CATIONIC PEPTIDES AND USES OF SAME | 07-07-2016 |
20160251375 | METHODS AND INTERMEDIATES FOR PREPARING MACROLACTAMS | 09-01-2016 |